RHHBY - Kronos to cut 19% of workforce focus on drugs KB-0742 lanraplenib
2023-11-02 16:47:29 ET
More on Kronos Bio
- Kronos Bio stock slightly up on positive preliminary data for investigational cancer drug
- Kronos Bio announces departure of CFO, Head of Corporate Development Al-Wakeel
- Seeking Alpha’s Quant Rating on Kronos Bio
- Historical earnings data for Kronos Bio
- Financial information for Kronos Bio
For further details see:
Kronos to cut 19% of workforce, focus on drugs KB-0742, lanraplenib